

To: Who it May Concern

Regarding: COVID-19 test conclusions and statement of facts in reference to Varigard Hand Sanitizer Complex and Varigard Surface Spray Complex.

Date: 2-23-21

The Protocols attached were executed at Synergy Labs (a government recognized Covid-19 testing facility) on Tuesday, February 23, 2021. The procedures listed were properly executed by Synergy Laboratory staff members with the cooperation of Varigard, LLC scientist. The Varigard Hand Sanitizer complex and the Varigard Surface Spray Complex both successfully achieved negative swab test results, indicating the Covid-19:B117 pathogen did not transfer to the swabbed surface. This test was performed in accordance to the attached written protocols, and the data representing the swab test were verified in accordance to laboratory testing guidelines. The test performed is an exact representation of the protocol provided and are not necessarily the full requirements of a regulatory submission document package. This is a statement of facts of the events and the test results, showing the absence of the Covid-19:B117 pathogen material on the swabbed surfaces.

Sincerely,

Brad Pitts/CEO



SYNERGY Laboratories

5570 Rangeline Rd.

Mobile, AL 36619

www.synergytesting.com

VARIGARD HYDROGEN PEROXIDE SURFACE SPRAY COMPLEX

SARS-CoV-2 (COVID-19)

PROTOCOL 1 (Positive Control Test)

PURPOSE:

The purpose of this test is to demonstrate that an actual SARS-CoV-2 (COVID-19) pathogen is being used for the remaining protocols in this test.

SCOPE:

The Scope of these tests includes preparing the SARS-CoV-2 (COVID-19) pathogen that will be applied to a clean surface for the following protocol.

OBJECTIVE:

The objective of this test is to show the presence of SARS-CoV-2 (COVID-19) pathogen in a controlled environment. The test will prove that after three (3) minutes the SARS-CoV-2 (COVID-19) pathogen will still be detectable and show a positive result. This test will be used as a control for the remaining protocols proving sequestration.

PROTOCOL NO. 01 – POSITIVE CONTROL TEST

1. Clean and disinfect a stainless-steel surface in a controlled environment under a laminar flow hood.
2. Apply LIVE SARS-CoV-2 (COVID-19) VIRAL PATHOGEN IN A LIQUID STATE. This application will be performed in a standard "X" pattern
3. Wait 3 minutes
4. Lab tech to use proper lab protocols for swabbing techniques to test for the presence of the SARS-CoV-2 (COVID-19) VIRAL PATHOGEN.

VARIGARD HYDROGEN PEROXIDE SURFACE SPRAY COMPLEX

(COVID-19 TEST)

PROTOCOL 2

(Sequester Pathogens for extended period of time)

PURPOSE:


The purpose of this test is to demonstrate how the Varigard Surface Spray using the Zero Thermal complex will perform when exposed to the SARS-CoV-2 (COVID-19) viral pathogen. We intend to demonstrate that the Varigard Surface spray will sequester SARS-CoV-2 (COVID-19) for extended periods of time after being applied.

SCOPE:

The Scope of these tests includes preparing the Varigard Surface Spray Complex and spraying the atomized solution on a disinfected stainless-steel surface. The surface will be divided into four (4) different sections. Two (2) of the sections will be used to apply live SARS-CoV-2 (COVID-19) pathogen.


1. Section #1-A: 20 hours
2. Section #2-A: 23 hours

Diagram 1.1- LIVE SARS-CoV-2 PATHOGEN PLACEMENT



The other two (2) sections represented by (B) will be used as the transfer surface for SARS-CoV-2 (COVID-19) pathogen. Each section will be labeled according to the timeframe and diagram listed below.

Diagram 1.1- LIVE SARS-CoV-2 PATHOGEN TRANSFER



After the time has expired for each Coupon, SARS-CoV-2 (COVID-19) pathogen will be applied to test for sequestration based on the following protocols.

OBJECTIVE:

The objective of these tests is to determine the efficacy of the Varigard Surface Spray complex to sequester SARS-CoV-2 (COVID-19) pathogens for extended periods of time. The test will prove that the Varigard complex will trap and sequester the SARS-CoV-2 (COVID-19) pathogen on contact and not allow the pathogen to be transferred to a secondary surface.

PROTOCOL NO. 02 - SARS-CoV-2 (COVID-19) SEQUESTRATION TEST

1. Four (4) sections are labeled according to the scope in this document (Diagram 1.1 and 1.2) in a controlled environment under a laminar flow hood.
2. Apply Varigard surface spray complex to each of the sections.

3. Wait the allocated time for each section (A) and then apply LIVE SARS-CoV-2 (COVID-19) VIRAL PATHOGEN IN A LIQUID STATE. This application will be performed in a standard "X" pattern
4. Using a new nitrile or latex glove, the surface where the SARS-CoV-2 (COVID-19) pathogen was placed will be touched with a flat palm.
5. The glove will then touch the corresponding surface (B) for each timed test with the palm down.
6. Lab tech to use proper lab protocols for swabbing techniques for the glove and the new surface (B) and test for the presence of the SARS-CoV-2 (COVID-19).

Repeat this for each of the time section 1-2 A&B. based on the dry times indicated.

Clinic Information

Client: Synergy Laboratories
5570 Rangeline Rd
Mobile, AL 36619
Requesting Physician / Practitioner:
Conner, Mitch M.D.

Patient Information

Patient Name: Varigard Hand Sanitizer -
2 hr glove, 15 SECOND CONTACT
Patient ID: P9923716
Date of Birth: 3/8/1988
Male/Female: Male
Patient Phone:
Current MME: N/A

Sample Information

Lab Sample ID: 21022343181
Specimen Type: Nasopharyngeal Swab
Collected On: 02/23/2021 05:40 PM
Received: 02/23/2021 05:40 PM
Reported: 02/24/2021 12:57 AM

Medications Prescribed

General Comment B117 UK STRAIN

Order Code(s)

GEN_COVID19

| Test | Normal | Abnormal | Reference Range | Units | Previous Result | Date |
|------------------------------|--------------|----------|-----------------|-------|-----------------|------|
| COVID-19 Interpretive Result | Not Detected | | -- | | | |
| Testing performed by RT-PCR. | | | | | | |

Positive results generated by any laboratory testing under the CDC EUA may be interpreted as positive instead of presumptive. No confirmation of positive results is required.

A negative result does not completely exclude infection by SARS-CoV-2, and should not be used as the sole basis for treatment or patient management decisions.

If COVID-19 is still suspected based upon exposure history together with other clinical findings, re-testing should be considered.

Repeat testing has been performed on all inconclusive results. Additional confirmation testing (such as an additional swab) should be conducted if clinically indicated.

Limitation: An absence of detection does not imply the absence of microorganisms other than those listed or does not exclude the possibility that the target sequence is present below the limit of detection. The Respiratory Microbiota Report does not take into consideration patient history, drug-drug-interactions, drug sensitivity, and/or allergies. It is the responsibility of the physician to determine appropriate drug and closing choices based on all available data.

Clinic Information

Client: Synergy Laboratories
5570 Rangeline Rd
Mobile, AL 36619
Requesting Physician / Practitioner:
Conner, Mitch M.D.

Patient Information

Patient Name: Varigard Surface Spray -
20 hr GLOVE, 15 SECOND CONTACT
Patient ID: P9923712
Date of Birth: 6/15/1958
Male/Female: Female
Patient Phone:
Current MME: N/A

Sample Information

Lab Sample ID: 21022346003
Specimen Type: Nasopharyngeal Swab
Collected On: 02/23/2021 10:34 AM
Received: 02/23/2021 10:34 AM
Reported: 02/24/2021 07:39 AM

Medications Prescribed

General Comment B117 UK STRAIN

Order Code(s)

GEN_COVID19

| Test | Normal | Abnormal | Reference Range | Units | Previous Result | Date |
|--|--------------|----------|-----------------|-------|-----------------|------|
| COVID-19 Interpretive Result | Not Detected | | -- | | | |
| Testing performed by RT-PCR. | | | | | | |
| <p>Positive results generated by any laboratory testing under the CDC EUA may be interpreted as positive instead of presumptive. No confirmation of positive results is required.</p> <p>A negative result does not completely exclude infection by SARS-CoV-2, and should not be used as the sole basis for treatment or patient management decisions.</p> <p>If COVID-19 is still suspected based upon exposure history together with other clinical findings, re-testing should be considered.</p> <p>Repeat testing has been performed on all inconclusive results. Additional confirmation testing (such as an additional swab) should be conducted if clinically indicated.</p> <p>Limitation: An absence of detection does not imply the absence of microorganisms other than those listed or does not exclude the possibility that the target sequence is present below the limit of detection. The Respiratory Microbiota Report does not take into consideration patient history, drug-drug-interactions, drug sensitivity, and/or allergies. It is the responsibility of the physician to determine appropriate drug and closing choices based on all available data.</p> | | | | | | |

Clinic Information

Client: Synergy Laboratories
5570 Rangeline Rd
Mobile, AL 36619
Requesting Physician / Practitioner:
Conner, Mitch M.D.

Patient Information

Patient Name: Varigard Surface Spray -
20 hr surface,15 SECOND CONTACT
Patient ID: P9923711
Date of Birth: 9/10/1962
Male/Female: Female
Patient Phone:
Current MME: N/A

Sample Information

Lab Sample ID: 21022346002
Specimen Type: Nasopharyngeal Swab
Collected On: 02/23/2021 10:33 AM
Received: 02/23/2021 10:33 AM
Reported: 02/24/2021 07:39 AM

Medications Prescribed

General Comment B117 - UK STRAIN

Order Code(s)

GEN_COVID19

| Test | Normal | Abnormal | Reference Range | Units | Previous Result | Date |
|------------------------------|--------------|----------|-----------------|-------|-----------------|------|
| COVID-19 Interpretive Result | Not Detected | | -- | | | |
| Testing performed by RT-PCR. | | | | | | |

Positive results generated by any laboratory testing under the CDC EUA may be interpreted as positive instead of presumptive. No confirmation of positive results is required.

A negative result does not completely exclude infection by SARS-CoV-2, and should not be used as the sole basis for treatment or patient management decisions.

If COVID-19 is still suspected based upon exposure history together with other clinical findings, re-testing should be considered.

Repeat testing has been performed on all inconclusive results. Additional confirmation testing (such as an additional swab) should be conducted if clinically indicated.

Limitation: An absence of detection does not imply the absence of microorganisms other than those listed or does not exclude the possibility that the target sequence is present below the limit of detection. The Respiratory Microbiota Report does not take into consideration patient history, drug-drug-interactions, drug sensitivity, and/or allergies. It is the responsibility of the physician to determine appropriate drug and closing choices based on all available data.